Cartherics, MUSC commercialization arm partner on TF-targeting cell therapy research
Cartherics has signed a research collaboration and option agreement with the Zucker Institute to test its iPSC-derived CAR-NK platform with a novel anti-tissue factor antibody. The work could support next-generation treatments for solid tumors and endometriosis, two areas with limited options.
Why it matters: - Cartherics is trying to broaden its off-the-shelf immune cell therapy pipeline beyond ovarian cancer and into other hard-to-treat diseases. - The collaboration could connect a clinically validated cancer target, tissue factor, with a cell therapy platform designed for solid tumors and possibly endometriosis. - Tissue factor is also emerging as a potential target in endometriosis, which could widen the commercial and medical scope of the program.
What happened: - Cartherics signed a research collaboration and option agreement with the Zucker Institute, the commercialization arm of the Medical University of South Carolina (MUSC). - The partners will study Cartherics’ induced pluripotent stem cell-derived CAR-NK platform with a novel anti-tissue factor antibody developed by MUSC researchers and the Regina Elena National Cancer Institute. - The collaboration was announced Sept. 1, 2026, from Melbourne, Australia.
The details: - The antibody was developed by Assoc Prof John Wrangle of MUSC and Dr Alessandra Metelli of the Regina Elena National Cancer Institute in Italy. - Cartherics will evaluate whether the antibody can be incorporated into next-generation TF-targeting CAR-NK therapies for solid tumors, including triple-negative breast cancer. - The companies will also explore potential use in endometriosis. - TF CAR-NK products will be tested in vitro and in vivo using human cancer and endometriosis models. - TF is highly expressed across many solid tumors and is linked to tumor progression, angiogenesis, invasion and metastasis. - TF is a clinically validated oncology target, including with a recent FDA approval of a TF-targeting antibody-drug conjugate for cervical cancer. - Emerging research has identified abnormal TF expression in endometriosis. - The antibody is designed to have a better safety profile than currently available anti-TF antibodies.
Between the lines: - The deal suggests Cartherics is trying to add a tumor-targeting component that could make its CAR-NK platform more versatile against solid tumors. - The option structure gives the companies room to test the science before committing to a deeper development path. - A single target with relevance in both cancer and endometriosis gives the program a rare cross-disease angle.
What's next: - Cartherics and the Zucker Institute will run preclinical studies to measure efficacy in relevant disease models. - The results will help determine whether the antibody-coupled CAR-NK approach advances toward a broader development program. - Cartherics will continue building on its iPSC-derived immune cell platform, which includes its lead product CTH-401 and additional CAR-immune cell candidates.
The bottom line: - Cartherics is pairing a stem cell-derived killer-cell platform with a novel antibody to target tissue factor in cancer and endometriosis, aiming to improve options in diseases where treatment choices remain limited.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Italy Education Times
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.